Facetten
Zugriff
Einrichtung
Medientyp
- Text 19
Karte
Erscheinungsjahr
Autor/in
- Reich, K
- Mrowietz, U 7
- Augustin, M 6
- Warren, R B 6
- Gottlieb, A B 3
- alle zeigen
Sprache
- Englisch 19
19 Einträge gefunden
-
Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis
2021 - Forschungsinformationssystem des UKE - frei zugänglich -
Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study
2021 - Forschungsinformationssystem des UKE -
-
Network meta-analyses in psoriasis: overview and critical discussion
2021 - Forschungsinformationssystem des UKE - frei zugänglich -
Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3
2021 - Forschungsinformationssystem des UKE - frei zugänglich -
-
-
The value of subcutaneous vs. oral methotrexate: real-world data from the German psoriasis registry PsoBest
2021 - Forschungsinformationssystem des UKE - frei zugänglich -
A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS)
2021 - Forschungsinformationssystem des UKE - frei zugänglich -
Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment
2021 - Forschungsinformationssystem des UKE - frei zugänglich -
Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3
2021 - Forschungsinformationssystem des UKE - frei zugänglich -
Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study
2021 - Forschungsinformationssystem des UKE - frei zugänglich -
Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2)
2021 - Forschungsinformationssystem des UKE - frei zugänglich -
Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies
2021 - Forschungsinformationssystem des UKE - frei zugänglich -
Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method
2021 - Forschungsinformationssystem des UKE - frei zugänglich -
A phase 4, randomized, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE)
2021 - Forschungsinformationssystem des UKE - frei zugänglich -
Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials
2021 - Forschungsinformationssystem des UKE - frei zugänglich -
Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2
2021 - Forschungsinformationssystem des UKE - frei zugänglich -
Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial
2021 - Forschungsinformationssystem des UKE - frei zugänglich